Author(s): Mason C, McCall MJ, CulmeSeymour EJ, Suthasan S, EdwardsParton S,
Abstract Share this page
Abstract During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3. Copyright © 2012 Elsevier Inc. All rights reserved.
This article was published in Cell Stem Cell
and referenced in Journal of Stem Cell Research & Therapy